U.S. Capital Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11M	Buy	1,432 +948	+196%	+$726K	0.03%	485
2025 Q4	$374K	Sell	484 -3	-0.6%	-$2.04K	0.01%	736
2025 Q3	$274K	Buy	487 +28	+6%	+$15.8K	0.01%	801
2025 Q2	$241K	Buy	459 +45	+11%	+$25.1K	0.01%	781
2025 Q1	$263K	Sell	414 -15	-3%	-$10.3K	0.01%	735
2024 Q4	$306K	Sell	429 -1,746	-80%	-$1.47M	0.01%	679
2024 Q3	$2.29M	Hold	2,175	–	–	0.08%	229
2024 Q2	$2.29M	Buy	2,175 +67	+3%	+$65K	0.09%	218
2024 Q1	$2.03M	Buy	2,108 +820	+64%	+$780K	0.08%	227
2023 Q4	$1.13M	Buy	1,288 +245	+23%	+$202K	0.04%	319
2023 Q3	$858K	Buy	1,043 +1	+0.1%	+$786	0.04%	340
2023 Q2	$749K	Buy	1,042 +180	+21%	+$139K	0.04%	373
2023 Q1	$708K	Buy	862 +1	+0.1%	+$754	0.03%	369
2022 Q4	$621K	Buy	+861	New	+$635K	0.03%	417

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

U.S. Capital Wealth Advisors's REGN Position: Q1 2026 in Review

U.S. Capital Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 196% in Q1 2026, buying an estimated $726K and bringing the position to 1,432 shares worth $1.11M. The position accounts for 0.03% of the portfolio, ranked #485.

U.S. Capital Wealth Advisors first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.29M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

U.S. Capital Wealth Advisors held 1,432 shares of Regeneron Pharmaceuticals worth $1.11M as of Q1 2026.
U.S. Capital Wealth Advisors bought 948 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $726K.
Regeneron Pharmaceuticals made up 0.03% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #485 holding.
U.S. Capital Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
U.S. Capital Wealth Advisors's Regeneron Pharmaceuticals position peaked at $2.29M in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.